Canagliflozin Date Wednesday, January 13, 2021 / Canagliflozin is the anhydrous form of canagliflozin, a C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type2diabetesmellitus. Read More
Cabazitaxel Date Monday, January 11, 2021 / Cabazitaxel is a semi-synthetic derivative of the natural Taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel is used to treat people with prostatecancer that has progressed despite treatment with docetaxel. It was approved by Food and Drug Administration (FDA) in 2010. Read More
Bortezomib Date Saturday, January 2, 2021 / Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. In May 2003, bortezomib became the first anticancerproteasome inhibitor that was approved by the FDA. Read More
Bupropion Date Tuesday, November 10, 2020 / Bupropion is an aminoketone with antidepressant activity. Bupropion is a unicyclic aminoketone that belongs to the class of substituted cathinones and the more general class of substituted phenethylamines. Bupropion is a medication primarily used to treat major depressivedisorder and to support smokingcessation. It was approved by the USFDA as an antidepressant. Read More
Budesonide Date Monday, November 9, 2020 / Budesonide is used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide belongs to the class of organiccompounds known as 21-hydroxysteroids. During the 2020 COVID-19 pandemic, researchers observed that patients already prescribed inhaled corticosteroids appeared to develop less serious illness when diagnosed with covid19 Read More
Brivaracetam Date Sunday, November 1, 2020 / Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. Brivaracetam is used in the treatment of partial-onset seizures. Brivaracetam was approval on February 19, 2016. Read More
Brexpiprazole Date Friday, October 30, 2020 / Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and major depressivedisorders. In January 2018, it was approved . Read More
Bosutinib Date Thursday, October 29, 2020 / Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Bosutinib was approved on September 4, 2012. Read More
Ampicillin Date Wednesday, October 28, 2020 / Ampicillin is a broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidalactivity. Ampicillin is an antibiotic used to prevent and treat a number of bacterialinfections, such as infections, urinary, meningitis, salmonellosis, and endocarditis. Ampicillin was discovered in 1958 and came into commercial use in 1961. Read More
Almotriptan Date Monday, October 26, 2020 / Almotriptan is a sulfonamide triptan with extracerebral, intracranial vasoconstrictor activity. Almotriptan is a triptan drug for the treatment of migraineheadaches. It was patented in 1992 and approved for medical use in 2000. Read More